Bausch Health Cos. said Thursday it plans to spin off its faster-growing eye-care business from its core pharmaceutical operations, breaking apart a company previous management had built through such acquisitions.
The eye-care unit, known as Bausch + Lomb, had $3.7 billion in revenue last year, compared with about $4.9 billion from the rest of the company.
Interested in talking to someone who was denied patient assistance by bauschhealth for a US $56k/year drug?
This should give some insight into its accounting fraud.
from Ye Olden Days $BHC $tsla $msft $googl $apo $lb currently down more than 86 percent from an August 2015 high of $262.52 and fell as low as $26.11 last week.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: